SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000891293-20-000031
Filing Date
2020-04-23
Accepted
2020-04-23 16:35:15
Documents
6
Period of Report
2020-04-23
Effectiveness Date
2020-04-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A ctic-2020proxystatementdef.htm DEF 14A 650745
2 acraignsignaturea05.jpg GRAPHIC 8270
3 acraignsignaturea06.jpg GRAPHIC 8270
4 cti1a01.jpg GRAPHIC 137247
5 cti2a01.jpg GRAPHIC 132552
6 ctia01.jpg GRAPHIC 5054
  Complete submission text file 0000891293-20-000031.txt   1053746
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-28386 | Film No.: 20811468
SIC: 2834 Pharmaceutical Preparations